Login
Israel-Hamas Conflict
Artificial Intelligence
Floods
Social Media
Drones
Natural Disasters
Benjamin Netanyahu
European Union
Education
Trade
Infrastructure
Stock Markets
Donald Trump
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Adalimumab Double Take: The Unexpected Return to Reference Humira

Summary by centerforbiosimilars.com
About 13% of patients who switch from Humira to an adalimumab biosimilar switch back to the originator, according to research from Truveta. However, the presented data may not tell the full story.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
centerforbiosimilars.comcenterforbiosimilars.com

Adalimumab Double Take: The Unexpected Return to Reference Humira

About 13% of patients who switch from Humira to an adalimumab biosimilar switch back to the originator, according to research from Truveta. However, the presented data may not tell the full story.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

centerforbiosimilars.com broke the news in on Monday, June 30, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

You have read 1 out of your 5 free daily articles.

News
For You
SearchBlindspotLocal